PD36-08 HIGH-DOSE ONABOTULINUMTOXIN A FOR MULTIPLE INDICATIONS IN THE NEUROUROLOGY PATIENT

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neurogenic Voiding Dysfunction (PD36)1 Sep 2021PD36-08 HIGH-DOSE ONABOTULINUMTOXIN A FOR MULTIPLE INDICATIONS IN THE NEUROUROLOGY PATIENT Robert Esterquest, Jamaal Jackson, Kevin Alter, Andrew Patton, Ravi Kasi, and Sarah Adelstein EsterquestRobert Esterquest More articles by this author , JacksonJamaal Jackson AlterKevin Alter PattonAndrew Patton KasiRavi Kasi AdelsteinSarah View All Author Informationhttps://doi.org/10.1097/JU.0000000000002040.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with neurogenic bladder often require multidisciplinary teams for care may multiple indications chemodenervation botulinumtoxin beyond bladder. The maximum FDA-approved dose is 400 units in a 3-month period. We aim assess incidence adverse events after off-label administration patients exceeding per 3 months. METHODS: electronic medical record one health system was queried retrospectively ICD-10 codes Parkinsonism (PD), spinal cord injury (SCI), or sclerosis (MS) undergoing cystoscopic the past years. Chart review performed on those receiving including spasticity rigidity physiatrist neurologist identify collected demographic clinical data, any report injections, descriptive statistics. RESULTS: total 52 PD, SCI, MS received intravesical during study Five out seven (71%) exceeded (ranging from 500 1200 units; median 575 units) There were no safety events, recorded reports weakness, dysphagia, difficulty breathing within four weeks administering these high treatments. CONCLUSIONS: None our series reported an event high-dose indications. Further into efficacy warranted complex population. Source Funding: © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e598-e598 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...